Key result
Persistent chylomicronemia linked to ~8% lower adipose tissue LPL DNA methylation vs controls.
Why the study?
Environmental modulators of DNA methylation can influence access to the LPL gene and may contribute to persistent chylomicronemia expression.
Does LPL DNA methylation in blood and adipose tissue differ between patients with persistent chylomicronemia, other hypertriglyceridemia, and normotriglyceridemic controls?
Observational (n=186)
No
Does LPL DNA methylation in blood and adipose tissue differ between patients with persistent chylomicronemia, other hypertriglyceridemia, and normotriglyceridemic controls?
Effect estimate: Δβ = 4.55% (CpG18), P = .002; Δβ = 7.70% (CpG19), P < .001 comparing PC vs other groups; Δβ = 5.13% (CpG18), P = .006 and Δβ = 7.93% (CpG19), P < .001 comparing PC of any cause vs controls
p-value: p=≤ .002 for CpG18 and < .001 for CpG19
Patients with persistent chylomicronemia exhibit a distinct lipoprotein lipase DNA methylation signature in adipose tissue, suggesting epigenetic factors may contribute to the condition.
Should not yet change persistent chylomicronemia management; hypothesis-generating for epigenetic LPL contributions and requires validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Larouche et al. (2026) conducted an observational in Persistent chylomicronemia and hypertriglyceridemia (n=186). Patients with persistent chylomicronemia had significantly lower DNA methylation at CpG18 and CpG19 in adipose tissue LPL gene by up to 7.70% compared to hypertriglyceridemic and normotriglyceremic controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: